Ichnos CEO On The ‘ASH Of Bispecifics’, Progress With Trispecific

 
• By Anju Ghangurde

Ichnos’ CEO Dr Cyril Konto highlights promising early data presented at ASH for the firm’s trispecific antibody in multiple myeloma versus teclistamab and alnuctamab. He also outlines why the US-based spin out of Glenmark isn’t considering the special purpose acquisition company alternative to the conventional IPO.  

Ichnos progresses myeloma assets • Source: Shutterstock

More from R&D

More from Scrip